Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
2(100.0%)
2Total
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07083479Unknown

Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma

Role: lead

NCT05726864Phase 1Active Not Recruiting

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Role: lead

NCT04853017Phase 1Completed

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Role: lead

All 3 trials loaded